Neurologia Śląska Centrum Medyczne

The trials here

What the 44 trials at this site are about, from their registry records.

Conditions

• Myasthenia gravis27 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)6 trials
• Tourette syndrome3 trials
• Migraine2 trials
• Multiple sclerosis2 trials
• Parkinson disease2 trials
• Alzheimer disease1 trial
• Multiple system atrophy1 trial

Phase

• Phase 324 trials
• Phase 212 trials
• Phase 2/34 trials
• Phase 1/22 trials
• Phase 11 trial
• Phase 41 trial

Status

• Recruiting18 trials
• Completed12 trials
• Active, not recruiting11 trials
• Not yet recruiting3 trials

Lead sponsor

• argenx9 trials
• UCB Biopharma SRL6 trials
• Immunovant Sciences GmbH4 trials
• Novartis Pharmaceuticals3 trials
• Dianthus Therapeutics2 trials
• and 17 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

  NCT07673744· Phase 2· TG Therapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

  NCT07673627· Phase 2· argenx· Source

• Recruiting

  A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

  NCT07647510· Phase 3· Dianthus Therapeutics· Source

• Recruiting

  A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis

  2025-525127-27-00· Phase 1/2· Aurinia Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· Phase 3· UCB Biopharma SRL· Source

• Active, not recruiting

  A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

  NCT07501702· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

  NCT07250750· Phase 1/2· ImmunAbs Inc.· Source

• Recruiting

  ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

  NCT07284420· Phase 2· argenx· Source

• Active, not recruiting

  A Phase 3b open-label, randomised study of IPX203 in subjects with advanced Parkinson’s disease and motor fluctuations - ADIP study

  2025-521772-57-00· Phase 3· Zambon Biotech S.A.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· argenx· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

• Recruiting

  Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

  NCT07039916· Phase 3· Immunovant Sciences GmbH· Source

• Recruiting

  Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT07032662· Phase 2· Immunovant Sciences GmbH· Source

• Enrolling by invitation

  An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

  NCT06435312· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

  NCT06055959· Phase 2/3· UCB Biopharma SRL· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

  NCT06558279· Phase 3· argenx· Source

• Active, not recruiting

  A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

  NCT06517758· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis

  2023-507539-40-00· Phase 2· NMD Pharma A/S· Source

• Active, not recruiting

  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

  NCT06456580· Phase 3· Vor Biopharma· Source

• Recruiting

  A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

  NCT06392386· Phase 2/3· argenx· Source

• Recruiting

  Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

  NCT06414954· Phase 2· NMD Pharma A/S· Source

  Contact: Marek Smilowski

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

  NCT06298552· Phase 3· argenx· Source

• Active, not recruiting

  A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

  NCT06282159· Phase 2· Dianthus Therapeutics· Source

• Active, not recruiting

  A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

  NCT06021522· Phase 3· Emalex Biosciences Inc.· Source

• Active, not recruiting

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Enrolling by invitation

  Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

  NCT05374590· Phase 2/3· argenx· Source

• Recruiting

  Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

  NCT05156398· Phase 3· Pfizer· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

  NCT05201638· Phase 3· Immunic AG· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

  NCT05156281· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

  NCT04833894· Phase 2/3· argenx· Source

• Recruiting

  A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  NCT04951622· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myasthenia gravis17 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
• Migraine1 recruiting

Closed trials

• Completed

  Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP

  2024-515386-34-00· Phase 2· Nuvig Therapeutics Inc.· Source

• Completed

  A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP

  2024-518364-12-00· Phase 2· Immunovant Sciences GmbH· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

  NCT06706622· Phase 3· H. Lundbeck A/S· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Cerevance· Source

• Active, not recruiting

  Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

  NCT06315751· Phase 2· Noema Pharma AG· Source

• Completed

  A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

  NCT06471361· Phase 3· UCB Biopharma SRL· Source

• Completed

  Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102

  2023-503729-20-00· Phase 1· Othair Prothena Limited· Source

• Completed

  Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.

  2024-512646-42-00· Phase 2· Immunovant Sciences GmbH· Source

• Completed

  Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

  NCT05615220· Phase 3· Emalex Biosciences Inc.· Source

• Completed

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· Phase 4· Pfizer· Source

• Completed

  Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

  NCT04225871· Phase 3· UCB Biopharma SRL· Source